Mainak Bardhan, Chief Scientific Officer, Chief of Medical Oncology and Deputy Director of Miami Cancer Institute, shared on X:

“This friday its about Miami Cancer Institute Research Precision Oncology symposium 2nd Annual at The Ritz-Carlton spearhead by one and only Manmeet Ahluwalia. These 2 days are packed up with wonderful experts oncology globally sharing their experience.

The best way to start the day is listening to Patrick Wen from Dana Farber regarding therapeutic avenues in high grade glioma and landscape of clinical trials in gliomas.

Insights of Ingo Mellinghoff  from Memorial Sloan Kettering Cancer Center regarding role of precision oncology in Low-grade glioma therapeutics focused on role of Isocitrate Dehydrogenase (IDH) mutations, IDH inhibitors roles, Vorasidenib and key lessons for successful clinical trials.

Manmeet Ahluwalia explaining the role of precision oncology in Brain metastases at Miami Cancer Institute Research Precision Oncology symposium. Lung, breast and skin cancers are top 3 sources of brain metastases. In lung cancer targeting EGFR, KRAS,ALK and RET have shown promise.

Manmeet Ahluwalia sharing work with Caris Life Sciences showing the role of Next generation sequencing (NGS) and machine learning in predicting brain metastases. Also Miami Cancer Institute Research is running its clinical trials on Focused low intensity Ultrasound and immunotherapy in Brain metastases, also is coordinating site of Intl Radiosurgery Research Foundation.

Neeta Somaiah from MD Anderson Cancer Center long term medical school friend Manmeet Ahluwalia of Maulana Azad Medical College discussing therapeutic landscape of Sarcomas targeting disease specific mutations like in KIT and PDGFRA for Gastrointestinal Stromal Tumor (GIST) at Miami Cancer Institute Research Precision Oncology Symposium.

Everett Vokes from UChicago Cancer Center an expert in Head and Neck cancer explaining various clinical trials targeted based therapies like Tipifarnib. Also he pointed some negative trials.

Very exciting talk by Reshma Mahtani from Miami Cancer Institute Research, Baptist Health sharing her expertise in role of precision medicine in treating triple negative.

Shilpa Gupta from Cleveland Clinic presented her expert views on Biomarkers in Urothelial cancers like targeting the Fibroblast Growth Factor Receptor (FGFR) in metastatic urothelial cancer and application of artificial intelligence.

Very timely and important discussion on Prostate Cancer therapeutics by Rohan Garje from Miami Cancer Institute Research Insights on theragnostic in Prostate Cancer treatment was exciting.

Vamsi Velcheti from New York University discussed about the treatment options for Metastatic Non small cell lung cancer(NSCLC), genotype -phenotype markers, 5 years Overall survival of important clinical trials, novel immune checkpoint inhibitors at Miami Cancer Institute Research Precision Oncology symposium.

Day 2 at Miami Cancer Institute Research Precision Oncology symposium is illuminated by Rachna Shroff’s talk on therapeutic landscape in hepatobilliary cancers, available targeted therapies and targets like FGFR2, MDM2.”

Source: Mainak Bardhan/X

About OncoDaily 

OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.

OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.

The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.